The FDA approved the first over-the-counter (OTC) naloxone nasal spray (Narcan, Emergent), making it available directly to consumers to rapidly reverse the effects of opioid overdose.
Naloxone is the standard treatment for opioid overdose.
In February, the FDA Nonprescription Drugs Advisory Committee and the Anesthetic and Analgesic Drug Products Advisory Committee unanimously voted that the benefit?risk profile of the 4-mg naloxone hydrochloride nasal spray supported its use as a nonprescription